Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo

See allHide authors and affiliations

Science Translational Medicine  21 Nov 2018:
Vol. 10, Issue 468, eaat6420
DOI: 10.1126/scitranslmed.aat6420

Antibodies to abrogate Andes hantavirus

Andes hantavirus circulates in rodent reservoirs and can cause hantavirus cardiopulmonary syndrome in humans, resulting in potentially lethal disease; no vaccines or targeted treatments exist. Garrido et al. screened memory B cells from people who had been infected with Andes hantavirus. Antibodies were isolated from one individual with a high viral neutralization capacity. Two of these antibodies were fully protective against disease in a hamster model, even when given several days after infection. These antibodies target distinct epitopes on the viral glycoprotein and could be developed for use alone or as a combination therapy.

View Full Text

Stay Connected to Science Translational Medicine